1167 Stock Overview
An investment holding company, engages in the in-house discovery and development of oncology therapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Jacobio Pharmaceuticals Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.29 |
| 52 Week High | HK$3.71 |
| 52 Week Low | HK$1.25 |
| Beta | 0.56 |
| 1 Month Change | -16.23% |
| 3 Month Change | -24.56% |
| 1 Year Change | -60.91% |
| 3 Year Change | -90.40% |
| 5 Year Change | n/a |
| Change since IPO | -91.05% |
Recent News & Updates
Recent updates
Does Jacobio Pharmaceuticals Group (HKG:1167) Have A Healthy Balance Sheet?
Nov 24
Most Shareholders Will Probably Agree With Jacobio Pharmaceuticals Group Co., Ltd.'s (HKG:1167) CEO Compensation
May 31Is Jacobio Pharmaceuticals Group (HKG:1167) Using Debt Sensibly?
May 29We're Hopeful That Jacobio Pharmaceuticals Group (HKG:1167) Will Use Its Cash Wisely
May 10Time To Worry? Analysts Are Downgrading Their Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Outlook
Aug 26We're Not Very Worried About Jacobio Pharmaceuticals Group's (HKG:1167) Cash Burn Rate
Jul 29We Think Jacobio Pharmaceuticals Group (HKG:1167) Can Afford To Drive Business Growth
Apr 29What Percentage Of Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Shares Do Insiders Own?
Mar 21Shareholder Returns
| 1167 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -6.5% | -3.9% | -0.5% |
| 1Y | -60.9% | -5.7% | 19.9% |
Return vs Industry: 1167 underperformed the Hong Kong Biotechs industry which returned -5.7% over the past year.
Return vs Market: 1167 underperformed the Hong Kong Market which returned 19.9% over the past year.
Price Volatility
| 1167 volatility | |
|---|---|
| 1167 Average Weekly Movement | 10.7% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in HK Market | 18.6% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 1167 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1167's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 298 | Yinxiang Wang | www.jacobiopharma.com |
Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies. The company’s drug development programs include Glecirasib (JAB-21822), a KRAS G12C inhibitor currently under multiple stage studies for indications, including NSCLC, PDAC, CRC and other solid tumors; JAB-3068, an SHP2 inhibitor approved by the FDA to enter clinical development for the treatment of esophageal cancer, including esophageal squamous cell carcinoma; and JAB-3312, an SHP2 inhibitor with multiple indications, such as KRAS G12C mut NSCLC under Phase III pivotal study, and Osimertinib progressed NSCLC under Phase I study, as well as NSCLC, HNSCC, and ESCC under Phase IIa studies. It also develops JAB-23E73 currently under IND-enabling studies for targeting multiple KRAS mutants indicated for PDAC, CRC, and NSCLC; JAB-BX300, a self-developed LIF mAb, under IND study indicated for the treatment of solid tumors; JAB-22000, a small-molecule KRAS G12D inhibitor, under lead optimization study indicated for PDAC, CRC, and NSCLC treatments; and JAB-8263, a Bromodomain and Extra-Terminal motif (BET) inhibitor, under Phase I studies indicated for MF, AML, and solid tumor.
Jacobio Pharmaceuticals Group Co., Ltd. Fundamentals Summary
| 1167 fundamental statistics | |
|---|---|
| Market cap | HK$1.02b |
| Earnings (TTM) | -HK$385.68m |
| Revenue (TTM) | HK$24.71m |
41.2x
P/S Ratio-2.6x
P/E RatioIs 1167 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1167 income statement (TTM) | |
|---|---|
| Revenue | CN¥23.19m |
| Cost of Revenue | CN¥22.38m |
| Gross Profit | CN¥801.00k |
| Other Expenses | CN¥362.69m |
| Earnings | -CN¥361.89m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.46 |
| Gross Margin | 3.45% |
| Net Profit Margin | -1,560.88% |
| Debt/Equity Ratio | 7.0% |
How did 1167 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 05:59 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jacobio Pharmaceuticals Group Co., Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ziyi Chen | Goldman Sachs |